Form 4: Phathom CFO Granted 200,000 Stock Options

Phathom Pharmaceuticals' Chief Financial and Business Officer, Sanjeev Narula, received a grant of 200,000 stock options with an exercise price of $11.61.

Summary

• Sanjeev Narula, Chief Financial & Business Officer of Phathom Pharmaceuticals, Inc. (PHAT), was granted 200,000 stock options.
• The options have an exercise price of $11.61 per share.
• The transaction date for this grant was October 6, 2025.
• The options will begin vesting on October 6, 2026, with 25% of the shares vesting on that date.
• The remaining shares will vest in equal monthly installments over the subsequent three years, contingent on Narula's continuous service to the Issuer.
• The stock options have an expiration date of October 5, 2036.
• Following this transaction, Narula beneficially owns 200,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed as a positive development, aligning management's interests with shareholders and incentivizing long-term performance. It reflects a standard practice in executive compensation.

Positives

• The grant of 200,000 stock options to the Chief Financial & Business Officer aligns executive incentives with shareholder value creation.
• The vesting schedule, tied to continuous service, encourages long-term commitment from a key executive.

Negatives

• No direct negatives are reported in this Form 4 filing.

Risks

• The value of the stock options is dependent on the future performance of Phathom Pharmaceuticals' common stock, posing a market risk to the executive's potential gains.
• The vesting schedule requires continuous service, meaning the executive could forfeit unvested options if employment ceases.

Future Outlook

The vesting schedule for the stock options indicates a long-term incentive structure, with initial vesting occurring on October 6, 2026, and subsequent monthly vesting over three years, contingent on the executive's continuous service to the company.

Industry Context

The grant of stock options to key executives is a common practice within the biotechnology and pharmaceutical industries, serving as a standard component of executive compensation packages designed to attract, retain, and incentivize leadership by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• The grant of stock options as a form of executive compensation is a widely adopted practice across the pharmaceutical and biotech sectors, comparable to companies like Pfizer, Moderna, or Biogen, which frequently use equity awards to incentivize their leadership.
• The vesting schedule, with a one-year cliff followed by monthly vesting over three years, is a common structure for executive equity grants, similar to those observed at peer companies, ensuring long-term retention and performance alignment.
• The exercise price of $11.61, likely the market price on the grant date, is standard for incentive stock options, reflecting the company's valuation at the time of the award.

Related Party Transactions

• The grant of 200,000 stock options to Sanjeev Narula, the Chief Financial & Business Officer, constitutes a transaction between the company and a key executive, which is a form of related party transaction. This is a standard component of executive compensation.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value creation, as the executive's financial gains are tied to stock price appreciation.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.
• Management: Provides a significant long-term incentive for the Chief Financial & Business Officer to remain with the company and contribute to its success.

Next Steps

• The stock options will begin vesting on October 6, 2026.
• The remaining options will vest in equal monthly installments over the subsequent three years.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Sanjeev Narula, stock options, executive compensation, insider transaction, Form 4, Chief Financial Officer, equity grant, vesting